Thejna John is a happy woman. Last year, the relapse of an acute form of blood cancer despite a bone marrow transplant, had made her doctors give up all hope.

In October, came a breakthrough. India approved the CAR T-Cell therapy, a revolutionary treatment for some forms of cancer. Thejna was one of the first cancer patients to undergo treatment in India. She is now cancer-free.  

The potential of CAR T-cell therapy is significant. And Pharma majors from Dr Reddy’s to Biocon are pouring in money into their own CAR T-Cell projects. But it’s early days. And questions remain: on efficacy, relapse, neurotoxicity and high costs.   

Join the conversation with host Anirban Chowdhury, Vikas Dandekar, ET's pharma expert, along with CAR T-Cell pioneer Dr. Hasmukh Jain, Associate Professor - Tata Memorial Centre, and Shirish Arya, Chief Business Officer - ImmunoACT as they discuss the future of this life-saving treatment on The Morning Brief podcast! Credits: TED